Preventing Re-infection With Hep C Post-Transplant
iTherX Initiates Phase 1b Study of First-in-Class Hepatitis C Virus Entry Inhibitor ITX-5061
— Preclinical Studies Show that ITX-5061 Prevents Hepatitis C from Invading Liver Cells —
SAN DIEGO, March 15, 2011 /PRNewswire/ — iTherX, a pharmaceutical company dedicated to discovering and developing a new class of therapies for hepatitis C, today announced that it has commenced patient recruitment in an open-label, proof-of-concept Phase 1b study of its lead compound ITX-5061 in liver transplant patients with hepatitis C virus infection (HCV). ITX-5061 represents a first-in-class compound that inhibits entry of the hepatitis C virus into liver cells.
“ITX-5061 possesses a unique mechanism of action that prevents the hepatitis C virus from entering liver cells and has demonstrated potent preclinical antiviral activity against all HCV genotypes. In addition, it has already demonstrated safety in more than 280 subjects,” said Jeffrey McKelvy, PhD, MD, President and Chief Executive Officer of iTherX. “We hope ITX-5061 will significantly improve long-term transplant outcomes.”
Continue reading this entire article: